Medical Cannabis for Multiple Sclerosis in the UK

Multiple sclerosis (MS) is one of the conditions with the strongest established evidence base for cannabis-based medicines in the UK. Nabiximols (Sativex), a cannabis-derived oromucosal spray, is the only cannabis-based medicine with a UK marketing authorisation, and it is licensed specifically for MS-related spasticity.

What is Multiple Sclerosis?

Multiple sclerosis is a chronic neurological condition in which the immune system attacks the myelin sheath — the protective covering of nerve fibres in the brain and spinal cord. This demyelination disrupts the electrical signals that nerves send and receive, causing a wide range of symptoms that vary between individuals and over the course of the disease.

In the UK, MS is one of the most common neurological conditions affecting young adults. It may follow a relapsing-remitting course, a secondary progressive course, or in fewer cases, a primary progressive course. Symptoms commonly include muscle stiffness and spasms (spasticity), fatigue, neuropathic pain, bladder dysfunction, visual disturbances, cognitive difficulties, and mobility impairment. Spasticity in particular is a significant cause of disability and is often inadequately controlled by standard oral antispastic agents such as baclofen or tizanidine.

Medical Cannabis and Multiple Sclerosis — What Does the Evidence Say?

MS represents one of the clearest cases in UK medicine for the clinical use of cannabis-based medicines. Sativex (nabiximols), a standardised extract containing THC and CBD in a 1:1 ratio, has been evaluated in multiple clinical trials for MS spasticity and carries a UK marketing authorisation for this indication. It is recommended by NICE as an option for moderate-to-severe spasticity in adults with MS when other treatments have not provided adequate relief — making it one of the few cannabis-derived medicines with formal NICE guidance in its favour.

Clinical trials have demonstrated that a meaningful proportion of patients with MS spasticity who do not respond adequately to conventional antispastics experience clinically significant reductions in spasm frequency and severity with nabiximols. Patient-reported outcomes regarding pain, sleep, and overall functioning have also been broadly positive in the MS context.

Who Qualifies for a Medical Cannabis Prescription for Multiple Sclerosis?

• Confirmed MS diagnosis: A formal diagnosis of multiple sclerosis, typically made by a neurologist.
• Qualifying symptoms: The most established indication is moderate-to-severe spasticity. Neuropathic pain associated with MS may also qualify.
• Failed conventional antispastics: At least two antispastic medications tried — such as baclofen and tizanidine — without adequate symptom control or with intolerable side effects.
• Specialist involvement: A neurologist or other relevant specialist must be involved in the prescribing decision.

What to Expect from a Medical Cannabis Consultation for MS

The consultation will focus on your neurological history, the nature and severity of your spasticity or pain, and the treatments you have already tried. The specialist will also review your MS type, disease-modifying therapies, and other current medications.

If nabiximols is prescribed, initial dosing for spasticity is typically titrated over several weeks. Response is formally assessed after a trial period, and treatment continues only in those who demonstrate a meaningful clinical benefit.

How Much Does Medical Cannabis Cost for MS in the UK?

• Initial consultation: £50 to £150 at a private cannabis clinic.
• Monthly medication: £150 to £400 per month depending on product and dose required.
• Follow-up appointments: £30 to £75 per session every one to three months.

Frequently Asked Questions — Medical Cannabis for MS UK

Is Sativex available on the NHS for MS?

Sativex has NICE approval for MS spasticity, but NHS prescribing is decided locally and remains inconsistent. Many patients who clearly qualify clinically find that their NHS trust does not currently fund it.

Can medical cannabis help with MS fatigue?

Evidence for cannabis-based medicines specifically improving MS fatigue is less strong than for spasticity. Some patients report subjective improvements; your specialist can discuss realistic expectations for your situation.

Will cannabis-based medicines interact with my MS disease-modifying therapy?

Known significant interactions are limited, but your specialist must be aware of your full medication list to assess potential interactions thoroughly.

I have progressive MS. Can I still access medical cannabis?

Yes, patients with secondary or primary progressive MS can be considered if they experience qualifying symptoms such as spasticity or neuropathic pain and have not responded adequately to conventional treatments.

Does cannabis affect bladder function in MS patients?

Some patients report modest positive effects on bladder symptoms, though this is not a primary licensed indication. Discuss your full symptom picture with your specialist.